Q-Line Biotech SME IPO
Q-Line Biotech IPO — date, price band, GMP & allotment 2026
Q-Line Biotech is a healthcare and biotechnology company engaged in the manufacturing and supply of diagnostic, pharmaceutical, and biotech-related products. Founded with a focus on quality healthcare solutions, the company serves hospitals, laboratories, and medical institutions through a customer-centric business model. It mainly operates across various Indian states while also exploring export opportunities. The company focuses on maintaining product quality, regulatory compliance, and expanding its presence in the growing healthcare sector.
Stock price
Q-Line Biotech is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 13 September.
- Open 21 May 2026
- Close 25 May 2026
- Allotment 26 May 2026
- Refund/credit 27 May 2026
- Listing 29 May 2026
Issue summary
The terms of the offer, as filed.
| IPO Dates | 21 to 25 May, 2026 |
|---|---|
| Price Band | ₹326 – ₹343 |
| Face Value | ₹10 |
| Lot Size | 400 Shares |
| Issue Size | ₹251 Cr |
| Registrar | Purva Sharegistry (India) Private Limited |
| Min Investment | ₹ 2,74,400 |
What will it cost me?
Bidding is in multiples of 400 shares at the ₹343 cut-off. The SME retail application is a fixed 2 lots; HNI starts at 3.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 2 | 800 | ₹2,74,400 |
| Retail (max) | 2 | 800 | ₹2,74,400 |
| HNI (min) | 3 | 1,200 | ₹4,11,600 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Strong presence in the diagnostic and IVD products industry across India.
- 02Wide product portfolio including biochemistry, molecular diagnostics, ELISA, and rapid test kits.
- 03Focus on indigenous manufacturing under the “Make in India” initiative.
- 04Experienced promoter leadership with healthcare industry expertise and nationwide distribution network.
- 05Strong emphasis on R&D, quality standards, and ISO-certified manufacturing processes.
Risks · 5
- 01Business depends heavily on the healthcare and diagnostics sector demand cycle.
- 02High competition from established multinational diagnostic and medical device companies.
- 03Regulatory changes in medical devices and diagnostic products may impact operations.
- 04Dependence on continuous innovation and new product approvals for growth.
- 05Any disruption in raw material supply or distributor network can affect business performance.
Where the money goes
How the company intends to use the proceeds of the issue.
About the company
The company is promoted by Saurabh Garg along with Amita Garg and other promoter group members. Q-Line Biotech follows a business model focused on indigenous manufacturing, imports, distribution, and after-sales support for diagnostic instruments and consumables. The company emphasises affordable healthcare solutions under the “Make in India” initiative while investing in research, quality control, and technology-driven manufacturing to strengthen its position in the Indian diagnostic industry.
Interested in this IPO? Check the live subscription status or browse all upcoming SME IPOs.
Frequently asked
What is the GMP of Q-Line Biotech?
The current Grey Market Premium is ₹108, or 31% over the issue price.
What is the Q-Line Biotech IPO price band?
₹326 to ₹343, on a face value of ₹10.
When is the allotment?
The basis of allotment is 26 May 2026, with listing on 29 May 2026.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — Purva Sharegistry (India) Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every SME and Mainboard issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
